Omega Fund Management, LLC Q4 2024 Filing
Filed February 14, 2025
Portfolio Value
$120.7B
Holdings
11
Report Date
Q4 2024
Filing Type
13F-HR
All Holdings (11 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 1 | BCAXBicara Therapeutics Inc. | 2,204,650 | $38.4B | 31.82% | |
| 2 | NUVBNuvation Bio | 13,072,340 | $34.8B | 28.81% | |
| 3 | REPLReplimune Group | 1,975,203 | $23.9B | 19.82% | |
| 4 | LXEOLexeo Therapeutics | 1,184,636 | $7.8B | 6.46% | |
| 5 | ALMSAlumis Inc | 653,223 | $5.1B | 4.25% | |
| 6 | —Ikena Oncology | 2,249,123 | $3.7B | 3.06% | |
| 7 | ENGNenGene Holdings Inc. | 526,357 | $3.5B | 2.90% | |
| 8 | IMUXImmunic Inc | 1,788,160 | $1.8B | 1.48% | |
| 9 | SANASana Biotechnology, Inc. | 843,750 | $1.4B | 1.14% | |
| 10 | ENGNWenGene Holdings Inc. | 321,502 | $271.1M | 0.22% | |
| 11 | SYRSSyros Pharmaceuticals | 251,270 | $57.8M | 0.05% |